Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from TruScreen Group Ltd. ( (AU:TRU) ) is now available.
TruScreen Group Limited successfully closed its Share Purchase Plan oversubscribed, raising approximately NZ$1.67 million, contributing to a total of NZ$4 million raised alongside a share placement. The funds will support TruScreen’s expansion in the Chinese market, distribution of HPV DNA products, and execution of cervical cancer screening programs in several countries. This capital raise is expected to enhance TruScreen’s market presence and drive the company towards profitability, reflecting strong shareholder support and strategic growth initiatives.
More about TruScreen Group Ltd.
TruScreen Group Limited is a medical device company specializing in AI-enabled technology for real-time cervical tissue abnormality detection. Their primary product, the TruScreen Ultra, is a cervical cancer screening device that eliminates the need for traditional sampling and laboratory infrastructure. The device is registered and approved for clinical use in multiple countries, including China, the UK, and Australia, and is distributed in over 20 countries.
Average Trading Volume: 411,455
Technical Sentiment Signal: Sell
Current Market Cap: A$12.38M
Find detailed analytics on TRU stock on TipRanks’ Stock Analysis page.